Editor’s Note: Welcome to “Let's Chat,” a blog series featuring contributions from members of the ophthalmic community. These blogs are an opportunity for ophthalmic bloggers to engage with readers with about a topic that is top of mind, whether it is practice management, experiences with patients, the industry, medicine in general, or healthcare reform. The series continues with this blog by Laura M. Periman, MD, and Ami A. Shah, MD. The views expressed in these blogs are those of their respective contributors and do not represent the views of Ophthalmology Times or MJH Associates.
Many medical specialties share medications and technologies, from various classes of drugs to diagnostic testing and surgical instruments. In ophthalmology, we tend to see ourselves as set apart from most specialties because of the unique needs and limitations of working with the eye. We’ve seen a few noticeable crossovers recently, however, particularly from aesthetics. Here are just a few “adopted” technologies we’re happy to see in the hands of ophthalmologists.
Intense pulsed light (IPL) therapy
IPL therapy has been used in aesthetics since the 1990s to improve skin texture and treat rosacea. First-generation platforms required tremendous expertise, but newer, sixth-generation technologies (Optima IPL with the OPT technology, Lumenis), coupled with corneal shields, have the safety profile needed to address the eyelid and adnexa, particularly targeting telangiectasias associated with ocular inflammation.
We do not yet have published papers comparing the clinical efficacy of treating directly on the eyelids (with large, laser-grade, corneal-shield protected globes) compared to treating outside the orbital rim (with disposable laser-grade external ocular shield stickers).
1. Liu R, Rong B, Tu P, et al. Analysis of Cytokine Level in Tears and Clinical Correlations After Intense Pulsed Light Treating Meibomian Gland Dysfunction. AJO. 2017 Nov;183: 81-90.
2. Craig JP, Chen YH, Turnbull PR. Prospective trial of intense pulsed light for the treatment of meibomian gland dysfunction. Invest Ophthalmol Vis Sci. 2015 Feb 12;56(3):1965-70.
3. unpublished data
4. Yin Y, Liu N, Gong L, Song N. Changes in the Meibomian Gland After Exposure to Intense Pulsed Light in Meibomian Gland Dysfunction (MGD) Patients. cure Eye Res. 2018 Mar;43(3): 308-313.
5. Scott AB, Miller JM, Shieh KR. Treating Strabismus by Injecting the Agonist Muscle with Bupivacaine and the Antagonist with Botulinum Toxin. Trans Am Ophthalmol Soc. 2009 Dec;107:104-109.
6. Romanov A, Pokushalov E, Ponomarev D, et al. Long-term suppression of atrial fibrillation by botulinum toxin injection into epicardial fat pads in patients undergoing cardiac surgery: Three-year follow-up of a randomized study. Heart Rhythm. 2019 Feb;16(2):172-177.
7. Park J, Park HJ. Botulinum Toxin for the Treatment of Neuropathic Pain. Toxins (Basel). 2017 Sep; 24;9(9):260.
8. Diel RJ, Kroeger ZA, Levitt RC, et al. Botulinum Toxin A for the Treatment of Photophobia and Dry Eye. Ophthalmology. 2018 Jan; 125(1): 139–140.
9. Ho MC, Hsu WC, Hsieh YT. Botulinum Toxin Type A Injection for Lateral Canthal Rhytids. JAMA Ophthalmol. 2014;132(3):332-337.
10. Lu R, Huang R, Li K, et al. The influence of benign essential blepharospasm on dry eye disease and ocular inflammation. Am J Ophthalmol. 2014 Mar;157(3):591-7.e1-2.
11. Gumus K, Lee S, Yen MT, Pflugfelder SC. Botulinum toxin injection for the management of refractory filamentary keratitis. Arch Ophthalmol. 2012 Apr;130(4):446-50.
12. Sahlin S, Chen E, Kaugesaar T. Effect of eyelid botulinum toxin injection on lacrimal drainage. Am J Ophthalmol. 2000 Apr;129(4):481-6.
13. Fouda SM, Mattout HK. Comparison Between Botulinum Toxin A Injection and Lacrimal Punctal Plugs for the Control of Post-LASIK Dry Eye Manifestations: A Prospective Study. Ophthalmol Ther. 2017 Jun;6(1):167-174.
14. Singh S, Ali MJ, Paulsen F. A review on use of botulinum toxin for intractable lacrimal drainage disorders. Int Ophthalmol. 2018 Oct;38(5):2233-2238.
15. Mérida S, Palacios E, Navea A, Bosch-Morell F. New Immunosuppressive Therapies in Uveitis Treatment. Int J Mol Sci. 2015 Aug 11;16(8):18778-95.
16. Goldberg RA, Lee S, Jayasundera T, et al. Treatment of lower eyelid retraction by expansion of the lower eyelid with hyaluronic Acid gel. Ophthalmic Plast Reconstr Surg. 2007 Sep-Oct;23(5):343-8.
17. Mancini R. Managing eyelid malpositions with hyaluronic acid gel injections. Int Ophthalmol Clin. 2013 Summer;53(3):11-20.